Sarepta therapeutics receives fast track designation for srp-9001 for the treatment of duchenne muscular dystrophy

Sarepta therapeutics receives fast track designation for srp-9001 micro-dystrophin gene therapy for the treatment of duchenne muscular dystrophy.sarepta therapeutics - study 102, a randomized, double-blind, placebo-controlled study of srp-9001, is ongoing with results expected in early 2021.sarepta therapeutics inc - srp-9001 has also been granted rare pediatric disease (rpd) designation..
SRPT Ratings Summary
SRPT Quant Ranking